144 related articles for article (PubMed ID: 17493353)
1. [JAK2V617F mutation in patients with idiopathic myelofibrosis].
Li WD; Li JY; Zhang SJ; Qiu HR; Xu W; Wang JS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):387-90. PubMed ID: 17493353
[TBL] [Abstract][Full Text] [Related]
2. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
3. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
4. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Singh N; Sazawal S; Upadhyay A; Chhikara S; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2015; 58(2):187-91. PubMed ID: 25885131
[TBL] [Abstract][Full Text] [Related]
5. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
[TBL] [Abstract][Full Text] [Related]
6. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
Chen YX; Li Y; Zhang LY; Liu X; Shan NN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
[TBL] [Abstract][Full Text] [Related]
7. [Incidence of JAK2V617F mutation in myeloproliferative diseases and its clinical significance].
Yuan LY; Li H; Chen GA; Ji DX; Gao LL; Rong JP; Yu H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Mar; 39(2):202-6. PubMed ID: 20387251
[TBL] [Abstract][Full Text] [Related]
8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
9. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
10. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
11. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
12. [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders].
Xu YY; Li HM; Li XJ; Yang L; Hu DM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):541-4. PubMed ID: 19549360
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
14. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
[TBL] [Abstract][Full Text] [Related]
15. [The clinical implication of JAK2 mutation expression in patients with myeloproliferative disorders].
Fei HR; Zhang R; Chen SN; Pan JL; Cen JN; Xue YQ
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):271-3. PubMed ID: 17637260
[TBL] [Abstract][Full Text] [Related]
16. [Correlations of jak2v617f mutation with clinical and laboratory findings in primary thrombocythemia patients].
Xia J; Xu W; Zhang SJ; Sun XM; Duan LM; Li WD; Qiou HX; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):416-20. PubMed ID: 18426677
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
18. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
Shen YF; Xia J; Lu MZ; Jiang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between socs3 mRNA expression and jak2v617f point mutation in bcr-abl negative patients with myelo-proliferative disease].
Wang DM; Pan L; Zhang JM; Li YH; Wang HF; Wang XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):479-83. PubMed ID: 18549612
[TBL] [Abstract][Full Text] [Related]
20. [MPLW515L point mutation in patients with myeloproliferative disease].
Xia J; Xu W; Zhang SJ; Fan L; Qiao C; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1421-4. PubMed ID: 19099657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
